■ Revisão crítica do tratamento medicamentoso da gota no Brasil.
Azevedo, Valderilio Feijó et al
Rev. Bras. Reumatol., Aug 2017, vol.57, no.4, p.346-355
■ Aspectos relevantes do diagnóstico e seguimento por imagem na gota
Fernandes, Eloy De Avila et a
Rev. Bras. Reumatol., Feb 2017, vol.57, no.1, p.64-72
■ 2016 updated EULAR evidence-based recommendations for the management of gout
P Richette, M Doherty, E Pascual et al
Annals of Rheumatic Diseases 2017, vol 76 (1)
http://ard.bmj.com/content/76/1/29
■ Gota: uma revisão
F Santos
Revista Médica da UFPR 2016, vol 3 (1)
http://revistas.ufpr.br/revmedicaufpr/article/view/46382/pdf
file:///C:/Users/User/Downloads/46382-177405-1-PB.pdf
■ Acido úrico: un nuevo factor contribuyente al desarrollo de obesidad?
Valenzuela M, Alex.
Rev. chil. nutr., Set 2016, vol.43, no.3, p.303-307
http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-75182016000300011&lng=en&nrm=iso
■ Diagnosis and treatment for hyperuricaemia and gout: a protocol for a systematic review of clinical practice guidelines and consensus statements
Q Li, X Li, J Kwong et al
BMJ Open 2016 (6)
http://bmjopen.bmj.com/content/7/6/e014928
http://bmjopen.bmj.com/content/bmjopen/7/6/e014928.full.pdf
■ Factors associated with initiation and persistent of urate-lowering therapy
Mats Dehlin, Emin Hoxha Ekström, Max Petzold et al
Arthritis Res Ther. 2017; 19: 6.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240247/
■ Guidelines for the treatment of gout: a Swiss perspective
H Wüthrich, F Alromaih, A So
Swiss Med Wkly 2016, vol 146: w14341
https://smw.ch/article/doi/smw.2016.14341/
■ Treatment of hyperuricemia in gout: current therapeuticas options, latest developments and clinical implication
Sebastian E. Sattui, Angelo L. Gaffo
Ther Adv Musculoskelet Dis. 2016 Aug; 8(4): 145–159
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959626/
■ The genetics of gout: towards personalized medicine?
Nicola Dalbeth, Lisa K. Stamp, Tony R. Merrima
BMC Med. 2017; 15: 108
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452604/
■ What makes gouty inflammation so variable?
Robert Terkeltaub
BMC Med. 2017; 15: 158
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561591/
■ Allopurinol and the risk of ventricular arrhythmias in the elderly: a study using US Medicare data
Jasvinder A. Singh, John Cleveland
BMC Med. 2017; 15: 59
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5361697/
■ Gout and subsequent erectile dysfunction: a population-based cohort study from England
Alyshah Abdul Sultan, Christian Mallen, Richard Hayward et al
Arthritis Res Ther. 2017; 19: 123
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461678/
■ Incidence of an risk factors for nephrolithiasis in patients with gout and the general population, a cohort study
- J. Landgren, L. T. H. Jacobsson, U. Lindström et al
Arthritis Res Ther. 2017; 19: 173.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5525359/
■ An optimal ultrasonography diagnostic test for early gout: a prospective study
E Norkuviene, M Petraitis, I Apanaviciene et AL
J Int Med Res 2017, vol 45 (4): 1417-1429
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625526/
■ Guidelines for the treatment of gout: a Swiss perspective
H Wüthrich, F Alromaih, A So
Swiss Med Wkly 2016, vol 146: w14341
■ Chronic tophaceous gout in patients with psoriasis
Lobato, Laís Cruz et al.
An. Bras. Dermatol., Feb 2017, vol.92, no.1, p.104-106
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962017000100104&lng=pt&nrm=iso
■ Use of febuxostat in the management of gout in the United Kingdom
Arabella Waller, Kelsey M. Jordan
Ther Adv Musculoskelet Dis. 2017 Feb; 9(2): 55–64
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315226/
■ Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options
Thomas Bardin, Pascal Richette
BMC Med. 2017; vol 15: 123
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494879/
■ Chronic tophaceous gout
M Jabalameli, A Bagherifard, H Hadi et al
QJM: An International Journal of Medicine 2017, vol 110 (4): 239-240
https://academic.oup.com/qjmed/article/110/4/239/2911047/Chronic-tophaceous-gout
■ Chronic tophaceous gout
R Angalla, A Mounir, S Driouich et al
QJM: An International Journal of Medicine 2017, vol 109 (10): 681-682
https://academic.oup.com/qjmed/article/109/10/681/2440068/Chronic-tophaceous-gout
■ Miliarial gout: a rare presentation of extensive cutaneous tophi
T –L Hung, W –M Wang, C –P Chiang
QJM: An International Journal of Medicine 2016, vol 109 (12)
■ Effectiveness of an electronic patient-centred self-management tool for gout sufferers: a cluster randomized controlled trail protocol
R O Day, L J Fresham, A D Nguyen et AL
BMU Open 2017, vol 16 (10): e017281
http://bmjopen.bmj.com/content/7/10/e017281
■ Lumbar spinal stenosis attributable to tophaceous gout: case report and review of the literature
W Wang, Q Li, W Liu
Ther Clin Risk Manag 2017, vol 13: 1287-1293
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628693/
■ Gout and comorbity: a nominal group study of people with gout
Singh JA.
Arthritis Res Ther. 2017 Sep 15;19(1):204
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603046/
■ Incident gout and erectile dysfunction: Is hyperuricaemia the elephant in the room?
A Abhishek, M Doherty
Arthritis Res Ther 2017, vol 19: 184
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5553804/
■ Factors associated with initiation and persistence of urate-lowering therapy
M Dehlin, E H Ekström, M Petzold et al
Arthritis Res Ther 2017, vol 19: 6
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240247/
■ Asymptomatic hyperuricemia and chronic kidney disease: narrative review of a treatment controversial
Theodoros Eleftheriadis, Spyridon Golphinopoulos, Georgios Pissas, Ioannis Stefanidis
J Adv Res. 2017 , vol 8(5): 555–56
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512148/
■ The role of hyperuricemia on vascular endothelium dysfunction
Haitao Zhen, Fen Gui
Biomed Rep. 2017 vol 7(4): 325–330
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590038/
■ Asymptomatic hyperuricemia is a strong risk factor for resistant hypertension in elderly subjects from general population
Alberto Mazza, Salvatore Lenti, Laura Schiavon, Alvise Del Monte et al
Biomed Pharmacother. 2017, vol 86: 590–594
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331939/
■ An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia
Marilisa Bove, Arrigo Francesco Giuseppe Cicero, Maddalena Veronesi, Claudio Borghi
Vasc Health Risk Manag. 2017; vol 13: 23–28
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308472/
■ Trea-to-target (T2T) recommendation for gout
U Kiltz, J Smolen, T Bardin, A C Solal et al
Annals of Rheumatic Diseases 2017, vol 76 (4)
http://ard.bmj.com/content/76/4/632
■ Artritis seudoséptica presenta sinovitis por cuerpo extraño en un paciente con gota
Valerio-Morales, IA et al.
Acta ortop. mex, Abr 2015, vol.29, no.2, p.123-126
http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S2306-41022015000200011&lng=en&nrm=iso
■ Diagnosis, treatment, and prevention of gout
B L Hainer, E Matheson, T Wilkes
American Family Physicians 2014, vol 90 (12): 831-836
http://www.aafp.org/afp/2014/1215/p831.html
■ Hiperuricemia y gota: el papel de la dieta
Álvarez-Lario, Bonifacio and Alonso-Valdivielso, J. L.
Nutr. Hosp., Abr 2014, vol.29, no.4, p.760-77
http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0212-16112014000400007&lng=en&nrm=iso
■ by Dr Paulo Fernando Leite
Cardiologia – Centro Médico Unimed BH
Rua Gonçalves Dias 202
Belo Horizonte/MG/Brasil
31 30033306 / 40204020
CRMMG: 7026
Email: pfleite1873@gmail.com